Preclinical Mouse Models of Pulmonary Disease: Acute Lung Injury, Acute & Severe Asthma, & Pulmonary Fibrosis

Presented By: 
Andrew Borkowski

Overview: Pulmonary disease is the third leading cause of death in the United States and continues to be a burden on public health across the world. While numerous treatments exist, that help ameliorate the symptoms of these diseases, the need for cures to these diseases remain in high demand. Biomodels offers proven preclinical models that test the efficacy of potential therapies targeting various pulmonary diseases including chronic obstructive pulmonary disease (COPD), allergic asthma, acute lung injury (ALI), adult respiratory distress syndrome (ARDS), as well as pulmonary fibrosis. Specifically, Biomodels has the capability to perform functional lung mechanics measurements including airway hyper-reactivity (flexiVentTM), bronchoalveolar lavage fluid (BALF) analysis, histopathology, immunohistochemistry as well as numerous other common laboratory tests. Biomodels has the unique capability of aerosolized, nose-only dosing with the use of the inExposeTM system in addition to other common routes of dosing (intranasal, intratracheal, intravenous, subcutaneous, intraperitoneal, oral gavage, etc.). Additionally, Biomodels downstream expertise and capabilities can provide a wealth of mechanistic insights through a variety of ex-vivo immunoassays that include multi-color flow cytometry, immunophenotyping, multiplex cytokine analyses, T cell specificity assays, Realtime PCR, and many more.

This webinar will showcase translational and predictive animal models of pulmonary disease. Additionally, the webinar will provide an overview of each clinical condition and how the utilization of both traditional and functional analyses in our animal models result in outcomes that will best predict how your therapeutic will behave in the clinic.

Request Slide Deck.